|
業務類別
|
Biotechnology |
|
業務概覽
|
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is thediscovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300. |
| 公司地址
| 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4 |
| 電話號碼
| +1 778 731-1711 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.nervgen.com |
| 員工數量
| 18 |
| Dr. Adam H. Rogers, M.D. |
Interim Chief Financial Officer, President and Chairman of the Board |
-- |
31/03/2026 |
|
|
| Dr. Randall E. Kaye,M.D. |
Director |
31/03/2026 |
| Dr. Harold M. Punnett |
Independent Director |
31/03/2026 |
| Mr. Neil A. Klompas, C.A. |
Independent Director |
31/03/2026 |
| Ms. Krista L. McKerracher |
Independent Director |
31/03/2026 |
| Dr. Adam H. Rogers, M.D. |
Interim Chief Financial Officer, President and Chairman of the Board |
31/03/2026 |
| Mr. J. Craig Thompson |
Lead Independent Director |
31/03/2026 |
| Mr. Brian E. Bayley |
Independent Director |
31/03/2026 |
| Mr. Gianni Ruffolo |
Independent Director |
31/03/2026 |
|
|
|
|